Advertisement
BEAM vs RXRX
Which Stock Would AI Choose? Beam Therapeutics (BEAM) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- BEAM has shown stronger recent momentum, with shares up approximately 24% over recent weeks amid positive gene-editing data and new financing.
- RXRX has experienced volatility, gaining modestly in recent weeks despite broader declines year-to-date, supported by AI partnership expansions.
- Both companies operate in innovative biotech spaces—BEAM in precision genetic medicines and RXRX in AI-driven drug discovery—but BEAM's market cap stands at $3.2 billion versus RXRX's $1.95 billion.
- BEAM benefits from narrower-than-expected Q4 losses and revenue growth, while RXRX beat EPS estimates but trades near 52-week lows.
- Investor sentiment favors BEAM with analyst targets implying significant upside, contrasting RXRX's recovery challenges.
Introduction
Beam Therapeutics (BEAM) and Recursion Pharmaceuticals (RXRX) represent cutting-edge approaches in biotechnology: precision base editing for genetic diseases and AI-powered drug discovery platforms, respectively. This stock comparison analyzes their recent market performance, business drivers, and relative positioning amid volatile biotech sector conditions. Traders seeking momentum plays and long-term investors eyeing clinical-stage innovators will find insights into growth potential, risks, and sentiment shifts in the current environment.
BEAM Overview and Recent Performance
Beam Therapeutics Inc. develops precision genetic medicines using base editing technology, targeting serious diseases like sickle cell disease and alpha-1 antitrypsin deficiency (AATD). Its pipeline includes therapies such as BEAM-302, a liver-targeting lipid nanoparticle (LNP) for AATD, and partnerships with Pfizer and others. In recent market activity, BEAM shares have surged around 24%, trading near $31 with a market cap of $3.2 billion. Positive influences include Phase 1/2 data publications, a new $500 million financing facility, and Q4 results showing narrower losses and year-over-year revenue growth to $114 million. These catalysts have boosted sentiment, with shares outperforming broader indices despite CEO share sales.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals Inc. leverages an AI-driven platform to decode biology and accelerate drug discovery across oncology, rare diseases, and more. Key assets include REC-4881 for familial adenomatous polyposis and collaborations with Roche, Bayer, and Sanofi. Recently, RXRX shares have traded around $3.70, with a $1.95 billion market cap, reflecting modest weekly gains but year-to-date softness. Developments driving activity include an expanded Citeline partnership for AI-powered clinical trial data and a CMO transition. Q4 EPS beat estimates at -$0.21, with revenue surging 672%, yet shares have declined post-earnings amid sector pressures, highlighting ongoing volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from over 350 available, each trading thousands of tickers across stocks, ETFs, and crypto with diverse strategies like swing trading, semiconductor focus, and volatility dips. These bots deliver impressive stats, including annualized returns from +15% to +168%, win rates of 54%–88%, and profit factors up to 11.7, with average trade durations spanning hours to weeks. Virtual Agents incorporate risk management, while Signal Agents suit flexible portfolios. Tailored to current market conditions, they target high-momentum sectors like tech and energy. Explore these bots to potentially enhance your trading edge in dynamic environments.
Head-to-Head Comparison
BEAM focuses on proprietary base editing for direct genetic corrections, contrasting RXRX’s broader AI platform mapping biological relationships to identify novel targets. Growth drivers for BEAM include clinical data readouts and financing strength, while RXRX emphasizes partnerships expanding its data ecosystem. Recent momentum favors BEAM with consistent uptrends versus RXRX’s choppy recovery. Both face biotech risks like trial failures and funding needs, but BEAM shows superior sector exposure in gene editing amid positive FDA signals. Market sentiment leans toward BEAM’s catalysts over RXRX’s execution hurdles.
Tickeron AI Verdict
Tickeron’s AI currently favors BEAM based on stronger trend consistency, recent price stability above key moving averages, and multiple catalysts like gene-editing progress and balance sheet bolstering. While RXRX offers AI innovation potential, its relative underperformance suggests higher near-term uncertainty. This positioning indicates a probabilistic edge for BEAM in prevailing market dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and RXRX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).
- BEAM’s FA Score: 1 green, 4 red.
- RXRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 2 bullish TA indicator(s).
- BEAM’s TA Score: 5 bullish, 3 bearish.
- RXRX’s TA Score: 2 bullish, 8 bearish.
Price Growth
BEAM (@Biotechnology) experienced а +16.08% price change this week, while RXRX (@Biotechnology) price change was +2.54% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.61%. For the same industry, the average monthly price growth was +8.78%, and the average quarterly price growth was +2225.89%.
Reported Earning Dates
BEAM is expected to report earnings on Aug 11, 2026.
RXRX is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (+2.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BEAM | RXRX | BEAM / RXRX | |
| Capitalization | 3.51B | 1.71B | 205% |
| EBITDA | -349.25M | -478.66M | 73% |
| Gain YTD | 23.160 | -21.027 | -110% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 164M | 65.7M | 250% |
| Total Cash | 1.21B | 654M | 185% |
| Total Debt | 251M | 72.4M | 347% |
BEAM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 93 | |
PRICE GROWTH RATING 1..100 | 38 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BEAM | RXRX | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 89% | 4 days ago 81% |
| Momentum ODDS (%) | 4 days ago 84% | 4 days ago 89% |
| MACD ODDS (%) | 4 days ago 82% | 4 days ago 88% |
| TrendWeek ODDS (%) | 4 days ago 80% | 4 days ago 82% |
| TrendMonth ODDS (%) | 4 days ago 78% | 4 days ago 81% |
| Advances ODDS (%) | 4 days ago 76% | 10 days ago 83% |
| Declines ODDS (%) | 10 days ago 84% | 5 days ago 88% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Aroon ODDS (%) | 6 days ago 64% | 4 days ago 88% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| COZX | 29.40 | 1.71 | +6.18% |
| Tradr 2X Long CORZ Daily ETF | |||
| IBTJ | 21.59 | 0.03 | +0.14% |
| iShares iBonds Dec 2029 Term Tr ETF | |||
| TSI | 4.46 | N/A | N/A |
| TCW Strategic Income Fund | |||
| APRJ | 25.11 | N/A | -0.02% |
| Innovator Premium Income 30 Bar ETF -Apr | |||
| DXIV | 71.67 | -0.13 | -0.17% |
| Dimensional International Vector Eq ETF | |||
RXRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with ABCL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then ABCL could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | +3.86% | ||
| ABCL - RXRX | 60% Loosely correlated | +1.65% | ||
| ABSI - RXRX | 60% Loosely correlated | +3.20% | ||
| CRSP - RXRX | 59% Loosely correlated | +1.88% | ||
| PRME - RXRX | 58% Loosely correlated | +2.22% | ||
| BEAM - RXRX | 56% Loosely correlated | +5.11% | ||
More | ||||